IV matrine is even more effective but he can't give it here (didn't explain why). Studies in China (written in Chinese) show 2 months IV matrine has 97% effectiveness for chronic coxsackie B myocarditis vs 0% in placebo
Im pretty sure he is referring to this study:
"Chen et al., Therapeutic effect of kangke injection on viral myocarditis and its anticoxsackie virus mechanism, Chinese Journal of Integrated Traditional and Western Medicine 1997; 17(4), 207-209)."
The study is quoted in his patent for oxymatrine.
https://www.google.com/patents/US8198293
"Clinically, intravenous matrine has been used to treat viral myocarditis in countries such as China. In one placebo-controlled study, more than 90% of the patients with chronic Coxsackievirus B myocarditis had an improvement of cardiac function, increase in lymphocyte number and function, and loss of viral markers when treated with intravenous matrine, as compared to 0% in the placebo-treated group."
My question is does anyone know if this study determined the type of Coxsackie B virus these patients with myocarditis had? I can only find the abstract not the full study and it only mentions "anti-Coxsackie group B virus neutralizing antibodies" but not the specific ones.
http://europepmc.org/abstract/med/9863092
Does anyone have the full study?
It would be interesting to see replications of this study with IV matrine to see if it has as good as result on patients with other symptoms (GI issues, myalgia, fatigue, etc) known to be caused by this virus and specifically the different CVB types. I understand that its a Th2 to Th1 shifter so the type of CVB shouldn't be as important as say in a targeted antiviral.
However with a more than 90% patient improvement response in symptoms with IV matrine compared to 50% with equilibrant it is definitely worth further investigation.